I have a 54-year-old male patient with stage IIIB non-small-cell lung cancer (NSCLC) of the right lower lobe. He had 1 episode of hemorrhagic pleural effusion that did not recur after drainage. The ...

Introduction Malignant pleural effusion (MPE) affects up to 15% of patients with cancer, and its incidence and prevalence are increasing. 1 - 4 Most cases are symptomatic; the most common symptoms are ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in the United States. It can cause a buildup of fluid around the lungs, known as pleural effusion. Roughly 80-85% of all lung ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Prolonged Lung Cancer Screening Boosts Mortality Benefit New data show that CT screening of individuals beyond 5 years can significantly increase survival benefits. Medscape Medical News, April 18, ...

Please provide your email address to receive an email when new articles are posted on . The average health care cost per patient in the indwelling pleural catheter (IPC) group was $40,179 vs. $46,640 ...

Researchers have unveiled a microfluidic device that significantly improves the separation of tumor cells and clusters from malignant effusions. This novel technology promises to advance the diagnosis ...

Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations. If you have the appropriate software installed, you can download article citation data ...